Our findings expand the possibilities for new potential therapeutic strategies, focused on insulin degradation, that could be used in the treatment and/or prevention of diseases related to hyperinsulinemia, such as obesity and T2DM. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.